Smith MR - Search Results

1

Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.

Smith MR, Antonarakis ES, Ryan CJ, Berry WR, Shore ND, Liu G, Alumkal JJ, Higano CS, Chow Maneval E, Bandekar R, de Boer CJ, Yu MK, Rathkopf DE. Smith MR, et al. Eur Urol. 2016 Dec;70(6):963-970. doi: 10.1016/j.eururo.2016.04.023. Epub 2016 May 6. Eur Urol. 2016. PMID: 27160947 Free PMC article. Clinical Trial.

2

Changes in body composition during androgen deprivation therapy for prostate cancer.

Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, Kantoff PW. Smith MR, et al. J Clin Endocrinol Metab. 2002 Feb;87(2):599-603. doi: 10.1210/jcem.87.2.8299. J Clin Endocrinol Metab. 2002. PMID: 11836291 Clinical Trial.

3

Osteoporosis during androgen deprivation therapy for prostate cancer.

Smith MR. Smith MR. Urology. 2002 Sep;60(3 Suppl 1):79-85; discussion 86. Urology. 2002. PMID: 12231056 Review.

4

Selective aromatase inhibition for patients with androgen-independent prostate carcinoma.

Smith MR, Kaufman D, George D, Oh WK, Kazanis M, Manola J, Kantoff PW. Smith MR, et al. Cancer. 2002 Nov 1;95(9):1864-8. doi: 10.1002/cncr.10844. Cancer. 2002. PMID: 12404279 Free article. Clinical Trial.

5

Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer.

Smith MR, Fallon MA, Goode MJ. Smith MR, et al. Urology. 2003 Jan;61(1):127-31. doi: 10.1016/s0090-4295(02)02006-x. Urology. 2003. PMID: 12559282

6

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.

Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Smith MR, et al. J Urol. 2003 Jun;169(6):2008-12. doi: 10.1097/01.ju.0000063820.94994.95. J Urol. 2003. PMID: 12771706 Clinical Trial.

7

Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.

Oh WK, Manola J, Bittmann L, Brufsky A, Kaplan ID, Smith MR, Kaufman DS, Kantoff PW. Oh WK, et al. Among authors: smith mr. Urology. 2003 Jul;62(1):99-104. doi: 10.1016/s0090-4295(03)00145-6. Urology. 2003. PMID: 12837431 Clinical Trial.

8

Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment.

Carroll PR, Benaron DA, Blackledge G, Coakley FV, D'Amico AV, Higano CS, Iversen P, Kattan M, Nanus DM, Nelson JB, Oh WK, Roach M 3rd, Sellers WR, Smith MR, McMann MC, Kantoff PW. Carroll PR, et al. Among authors: smith mr. J Urol. 2003 Dec;170(6 Pt 2):S3-5. doi: 10.1097/01.ju.0000095101.18470.a0. J Urol. 2003. PMID: 14610403 Review. No abstract available.

9

Bisphosphonates to prevent skeletal complications in men with metastatic prostate cancer.

Smith MR. Smith MR. J Urol. 2003 Dec;170(6 Pt 2):S55-7; discussion S57-8. doi: 10.1097/01.ju.0000095102.34708.bc. J Urol. 2003. PMID: 14610411 Review.

10

Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.

Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Diamond TH, et al. Among authors: smith mr. Cancer. 2004 Mar 1;100(5):892-9. doi: 10.1002/cncr.20056. Cancer. 2004. PMID: 14983482 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,145 results

Search Page